AR126473A1 - Derivados de 6h-imidazo[1,2-a]pirrolo[2,3-e]piridina para su uso en terapia - Google Patents
Derivados de 6h-imidazo[1,2-a]pirrolo[2,3-e]piridina para su uso en terapiaInfo
- Publication number
- AR126473A1 AR126473A1 ARP220101871A ARP220101871A AR126473A1 AR 126473 A1 AR126473 A1 AR 126473A1 AR P220101871 A ARP220101871 A AR P220101871A AR P220101871 A ARP220101871 A AR P220101871A AR 126473 A1 AR126473 A1 AR 126473A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- formula
- cancer
- alkyl group
- group
- Prior art date
Links
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 11
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 abstract 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 abstract 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 229910017711 NHRa Inorganic materials 0.000 abstract 1
- 206010029260 Neuroblastoma Diseases 0.000 abstract 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract 1
- 208000024770 Thyroid neoplasm Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 239000003098 androgen Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 abstract 1
- 125000005549 heteroarylene group Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 abstract 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 1
- 201000002510 thyroid cancer Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, en donde R¹ representa un átomo de hidrógeno, un grupo alquilo (C₁-C₄), un átomo de halógeno o un grupo fluoroalquilo (C₁-C₄), R² representa un átomo de hidrógeno, un grupo alquilo (C₁-C₃), un cicloalquilo (C₃-C₆), un grupo fluoroalquilo (C₁-C₃), un grupo C(O)NHRᵃ o un átomo de halógeno, en donde Rᵃ es un grupo alquilo (C₁-C₃), R³ representa un átomo de hidrógeno, un grupo alquilo (C₁-C₄), un grupo fluoroalquilo (C₁-C₄) o un átomo de halógeno, y Ar representa un grupo heteroarileno (C₅-C₆) o un anillo aromático divalente. Reivindicación 5: Proceso para preparar un compuesto de fórmula (1) en donde Ar, R¹ y R² son como se definió en una cualquiera de las reivindicaciones 1 a 3 y R³ es un átomo de halógeno, en donde un compuesto de fórmula (2) en donde Ar, R¹ y R² son como se definió en una cualquiera de las reivindicaciones 1 a 3, se hace reaccionar con un derivado de succinimida de fórmula (3), en donde R³ es un átomo de halógeno, en un disolvente, tal como tetrahidrofurano, diclorometano, cloroformo o tolueno, en una atmósfera inerte. Reivindicación 6: El proceso según la reivindicación 5, en donde el compuesto de fórmula (2) se obtiene haciendo reaccionar un compuesto de fórmula (6) con un compuesto de fórmula (5), en donde Ar, R¹ y R² son como se definió en una cualquiera de las reivindicaciones 1 a 3. Reivindicación 7: Proceso para preparar un compuesto de fórmula (1), en donde Ar, R¹ y R² son como se definió en una cualquiera de las reivindicaciones 1 a 3 y R³ se selecciona de entre un grupo alquilo (C₁-C₄) o un grupo fluoroalquilo (C₁-C₄), en donde un compuesto de fórmula (6), en donde Ar y R¹ son como se definió en cualquiera de las reivindicaciones 1 a 3 y R³ se selecciona de entre un grupo alquilo (C₁-C₄) o un grupo fluoroalquilo (C₁-C₄), se hace reaccionar con un compuesto de fórmula (5), en donde R² es como se definió en una cualquiera de las reivindicaciones 1 a 3. Reivindicación 11: Un compuesto de fórmula (1) según cualquiera de las reivindicaciones 1 a 4, o una sal farmacéuticamente aceptable del mismo, para su uso en la prevención y/o el tratamiento de trastornos autoinmunitarios, enfermedades neurodegenerativas, traumatismos cerebrales, enfermedades psiquiátricas, enfermedades inflamatorias y/o cáncer, más concretamente del cáncer. Reivindicación 12: Un compuesto para su uso según la reivindicación 11, en donde el cáncer es un tumor sólido, concretamente neuroblastoma, cáncer colorrectal, cáncer de vejiga inducido por andrógenos, cáncer de pulmón, carcinoma hepatocelular, cáncer de mama, cáncer de esófago y cáncer de tiroides.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21306000 | 2021-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126473A1 true AR126473A1 (es) | 2023-10-11 |
Family
ID=77126713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101871A AR126473A1 (es) | 2021-07-16 | 2022-07-15 | Derivados de 6h-imidazo[1,2-a]pirrolo[2,3-e]piridina para su uso en terapia |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240294529A1 (es) |
| EP (1) | EP4370516A1 (es) |
| JP (1) | JP2024525792A (es) |
| CN (1) | CN118234727A (es) |
| AR (1) | AR126473A1 (es) |
| TW (1) | TW202320753A (es) |
| WO (1) | WO2023285465A1 (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2928923B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques |
| FR2928922B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique |
| FR2950344B1 (fr) * | 2009-09-18 | 2011-11-25 | Sanofi Aventis | Derives de 5-phenyl-pyrazolopyridine, leur preparation et leur aplication en therapeutique. |
| WO2019098699A1 (ko) * | 2017-11-15 | 2019-05-23 | 한국생명공학연구원 | 다이터펜계 화합물을 포함하는 신경퇴행성 질환 예방 또는 치료용 조성물 |
-
2022
- 2022-07-12 JP JP2024502014A patent/JP2024525792A/ja active Pending
- 2022-07-12 EP EP22747695.9A patent/EP4370516A1/en active Pending
- 2022-07-12 CN CN202280059586.1A patent/CN118234727A/zh active Pending
- 2022-07-12 US US18/578,547 patent/US20240294529A1/en active Pending
- 2022-07-12 WO PCT/EP2022/069471 patent/WO2023285465A1/en active Application Filing
- 2022-07-14 TW TW111126437A patent/TW202320753A/zh unknown
- 2022-07-15 AR ARP220101871A patent/AR126473A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024525792A (ja) | 2024-07-12 |
| TW202320753A (zh) | 2023-06-01 |
| EP4370516A1 (en) | 2024-05-22 |
| US20240294529A1 (en) | 2024-09-05 |
| CN118234727A (zh) | 2024-06-21 |
| WO2023285465A1 (en) | 2023-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100191193B1 (ko) | 6환 화합물 | |
| AU2016248366B2 (en) | Heterocycles useful as IDO and TDO inhibitors | |
| KR102702618B1 (ko) | 면역조절제 | |
| MX2018014871A (es) | Proceso de preparacion de n-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4, 5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida . | |
| AU2019265346B2 (en) | Heteroaryl compounds and uses thereof | |
| EA027139B1 (ru) | Замещенные 5-(3,5-диметилизоксазол-4-ил)индолин-2-оны | |
| KR20190038485A (ko) | Fgfr4 저해제인 헤테로 고리 화합물 | |
| EP3676264A1 (en) | Pikfyve kinase inhibitors | |
| US9416142B2 (en) | Griseofulvin derivatives | |
| JP2018527340A5 (es) | ||
| AR126473A1 (es) | Derivados de 6h-imidazo[1,2-a]pirrolo[2,3-e]piridina para su uso en terapia | |
| Barbero et al. | An efficient copper-catalytic system for performing intramolecular O-arylation reactions in aqueous media. New synthesis of xanthones | |
| JP2006503079A (ja) | 抗癌化合物 | |
| JP2014527508A5 (es) | ||
| WO2012010555A1 (en) | Tricyclic lactones for treatment of cancer | |
| CN115119508B (zh) | 大环tlr7激动剂、其制备方法、药物组合物及其用途 | |
| WO2012007619A1 (es) | Proceso de obtención de derivados solubles en agua de 20(s)camptotecina como agentes antitumorales | |
| MXPA04011682A (es) | Camptotecinas con un anillo lactona modificado. | |
| CN114616234B (zh) | 磷咪唑并喹啉胺衍生物、及其药物组合物和应用 | |
| Liu et al. | Total synthesis of (S)-14-azacamptothecin | |
| AR126471A1 (es) | Derivados de imidazo[1,2-b][1,2,4]triazol para uso terapéutico | |
| Baraldi et al. | Synthesis and cytostatic activity of geiparvarin analogs | |
| AR121666A1 (es) | DERIVADOS DE NAFTIRIDINA Y PIRIDO[3,4-C]PIRIDAZINA COMO MODULADORES DEL RECEPTOR GABAA a5 | |
| KR20030031481A (ko) | Ｅｔ-743의 항종양성 동족체 | |
| SU1047391A3 (ru) | Способ получени производных рифамицина |